ACXP Acurx Pharmaceuticals NASDAQ 10 Mar 2026: Ibezapolstat trial headlines earnings

ACXP stock climbed 48.34% to $2.90 on 10 Mar 2026 after Acurx Pharmaceuticals announced a new ibezapolstat trial and confirmed an earnings call for 13 Mar 2026. The move came on 31,258,669 shares traded, vastly above the 50-day average of 157,135 shares. We examine what the trial update means for the upcoming ACXP earnings, valuation, and the path to Phase 3 and potential approvals.

Earnings spotlight: ACXP stock reaction and upcoming call

ACXP stock surge is tied to a March 9 press release and the company’s earnings call scheduled for 13 Mar 2026. The company said the new open-label rCDI pilot trial will enroll up to 20 patients and will inform a planned Phase 3 registration trial. The earnings call will review full year 2025 financials and outline trial timing and funding needs.

Investors should note the official earnings announcement time is 08:30 AM ET on 13 Mar 2026 and Acurx will host management and R&D on the call to answer questions about ibezapolstat.

Pipeline catalyst: ACXP stock and ibezapolstat Phase 3 readiness

Acurx said ibezapolstat is Phase 3 ready pending funding and regulatory clarity. The Phase 2 pooled data show a 96.00% clinical cure and 100.00% sustained cure at one month in treated patients. The company plans a 1:1 randomized Phase 3 design versus vancomycin with an estimated 450 mITT subjects in the initial trial.

These clinical results and the company’s QIDP and Fast-Track designations are the primary near-term catalysts for ACXP stock and the topic likely to dominate the earnings discussion. For the full company release see PR Newswire and the Nasdaq summary at Nasdaq.

Financials and valuation: ACXP stock metrics you must know

Acurx trades on NASDAQ in the United States with a market cap of $4,596,436.00 and 1,584,978 shares outstanding. The company reported EPS of -8.18 and a negative PE of -0.35, reflecting pre-revenue, clinical-stage status. Cash per share is 3.63 and book value per share is 2.24.

Key ratios show a Price/Book near 1.29 and a current ratio of 2.47, indicating short-term liquidity coverage. These figures frame ACXP stock valuation as speculative and dependent on clinical progress and funding.

Technical view: ACXP stock trading signals and volatility

Price closed at $2.90 after intraday range $2.08–$3.13, with relative volume of 198.49 and average volume 157,135. Momentum indicators are stretched: RSI is 69.90, MFI 98.84 (overbought), and CCI 338.22. ATR is 0.27, which implies sizable intraday swings for a low-cap stock.

Investors should expect high volatility; watch the 50-day average price 2.30 and 200-day average price 5.15 as reference points for short- and medium-term trend decisions.

Meyka AI grade and analyst consensus on ACXP stock

Meyka AI rates ACXP with a score of 67.33 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model blends quantitative metrics and forecast data to produce the grade.

Independent analyst signals show 2 Buy recommendations and no holds or sells in the upgrade/downgrade consensus, producing a consensus score of 4.00 on the available tracker.

Risks, timeline, and what to watch for ACXP stock

Primary risks are funding the Phase 3 program, enrollment delays, and regulatory outcomes. Acurx noted that advancement to Phase 3 is subject to securing appropriate funding. The company also highlighted a potential regulatory shift to a one-trial registration standard, which could shorten timelines if formalized.

Key near-term items: the 13 Mar 2026 earnings call, any clarity on Phase 3 funding, and additional microbiome or recurrence data disclosures expected after scientific meetings in July 2026.

Final Thoughts

ACXP stock moved sharply on 10 Mar 2026 as investors priced the new ibezapolstat rCDI pilot and Phase 3 readiness into the near term. Current price is $2.90 with a market cap near $4.60 million USD and heavy intraday volume of 31,258,669 shares. Meyka AI’s forecast model projects a 12‑month price of $3.95, which implies an upside of 36.21% versus today’s price. Meyka AI’s forecast model projects a quarterly target of $3.51 and a 3‑year view of $5.61. These model-based projections are not guarantees and assume successful trial progress and timely funding. For earnings-focused traders, the March 13 earnings call will be the immediate event to watch. We will monitor enrollment, regulatory feedback, and any additional safety or microbiome data that influence ACXP stock momentum. As always, this analysis is informational and not investment advice, and investors should consider the high clinical and funding risk typical of late-stage biotech.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.